Draxis Health reported third-quarter revenues of $9.7 million, up 20% compared with the $8 million reported last year. For the quarter (end-September 30), the Mississauga, Ontario-based firm had net income of $259,000, compared with a net loss of $421,000 in the third quarter of 2000.
The firm's radiopharmaceutical subsidiary, DraxImage, reported a 19% increase in radiopharmaceutical revenue in the third quarter. DraxImage is working to install a second robotic BrachySeed production line, which is expected to launch in the fourth quarter to meet growing seed demand in the U.S., according to Draxis.
BrachySeed I-125 sales grew 244% to $244,000 in the third quarter, up from $71,000 in the second quarter, according to the company's U.S. marketing partner, Cytogen of Princeton, NJ.
By AuntMinnie.com staff writersNovember 8, 2001
Related Reading
DraxImage to make radiotherapy capsules for Bracco, August 23, 2001
Draxis posts higher revenues in Q2, August 13, 2001
DraxImage gets clearance for palladium version of BrachySeed, June 28, 2001
DraxImage gets new president, June 20, 2001
DraxImage files for approval for brachytherapy implant, April 27, 2001
Copyright © 2001 AuntMinnie.com
